drugset / Trial / NCT04116502
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
Phase 3
Recruiting
586 enrolled
University of Birmingham
MPN Voice · collabNational Cancer Institute, France · collabNovartis · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a choice of interferon alpha, any formulation permitted (IFN) or hydroxycarbamide (HC), and which will be elected by the Investigator prior to randomisation.
Timeline
- Start
- 2019-10-25
- Primary completion
- 2028-10-31
- Completion
- 2030-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Hydroxyurea | Other / unclassified | — | — |
| Subject | Ruxolitinib | Small molecule | 10 mg | — |
| Comparator | interferon alfa-2b | Protein / enzyme biologic | — | — |